Compare MRVI & BETR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRVI | BETR |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.8M | 538.7M |
| IPO Year | 2020 | N/A |
| Metric | MRVI | BETR |
|---|---|---|
| Price | $3.41 | $37.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $4.13 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 1.9M | 517.6K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $185,743,000.00 | N/A |
| Revenue This Year | $12.44 | $54.06 |
| Revenue Next Year | $7.90 | $66.68 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.70 | $10.81 |
| 52 Week High | $4.11 | $94.06 |
| Indicator | MRVI | BETR |
|---|---|---|
| Relative Strength Index (RSI) | 60.33 | 54.97 |
| Support Level | $3.25 | $26.89 |
| Resistance Level | $3.99 | $41.23 |
| Average True Range (ATR) | 0.17 | 3.39 |
| MACD | 0.07 | 0.17 |
| Stochastic Oscillator | 81.08 | 48.02 |
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
Better Home & Finance Holding Co is a technology-enabled homeownership company that provides mortgage, home equity, and related services through a digital platform. The company operates through two reportable segments: Home Finance, which focuses on residential mortgage origination, including purchase, refinance, and home equity products, generating revenue mainly from loan sales; and Banking, which, through its U.K. subsidiary Birmingham Bank, offers a range of financial products and services to consumers and small businesses. It generates the majority of its revenue from the Home Finance segment.